Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093310 | 0.83 | MAPT (0.37) | MAPTTSHR | |
| SCHEMBL17266586 | 0.82 | MAPT (0.39) | MAPTTSHR | |
| Methacrylic Acid SCHEMBL7860381 | 0.82 | TSHR (0.44) | MAPTTSHRALDH1A1 | |
| SCHEMBL28265728 | 0.81 | FAAH (0.41) | TSHRALDH1A1 | |
| SCHEMBL28421477 | 0.81 | CTSK (0.32) | MAPTALDH1A1 | |
| SCHEMBL28445985 | 0.80 | LMNA (0.41) | MAPTTSHRALDH1A1 | |
| SCHEMBL22551148 | 0.80 | FAAH (0.47) | MAPTALDH1A1 | |
| SCHEMBL10456507 | 0.79 | MAPT (0.38) | MAPTTSHR | |
| SCHEMBL3205780 | 0.78 | MAPT (0.37) | MAPTTSHR | |
| SCHEMBL27046 | 0.78 | MAPT (0.37) | MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341215-A | Curable composition | 株式会社日本触媒 | 2022-04-12 | — | — | CN | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-0050492-B1 | 1,1-DISUBSTITUTED-HEXAHYDRO-INDOLO(2,3-A)QUINOLIZINE DERIVATIVES AND THEIR USE IN THE ENANTIOSELECTIVE SYNTHESIS OF OPTICALLY ACTIVE 14-OXO-E-HOMO-EBURNANE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-08-15 | — | — | EP | disclosed |
| US-4446139-A | Hexahydroindoloquinolizinium and octahydroindoloquinolizine esters, and method of increasing blood flow in an animal with hydroxyamino-eburnane derivatives | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1984-05-01 | — | — | US | disclosed |
| US-4345082-A | VASODILATION | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1982-08-17 | — | — | US | disclosed |
| EP-0050492-A1 | 1,1-Disubstituted-hexahydro-indolo(2,3-a)quinolizine derivatives and their use in the enantioselective synthesis of optically active 14-oxo-E-homo-eburnane derivatives | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1982-04-28 | — | — | EP | disclosed |
| US-4278808-A | Method of preparing a 3-alkoxy-2-alkyl-propionic acid ester derivative and intermediate therefor | BRACCO INDUSTRIA CHIMICA S.P.A. (IT) | 1981-07-14 | — | — | US | disclosed |
| EP-0003115-A1 | Penicillins, per se and for use as antibacterially active antibiotics and their production | SANDOZ AG (CH) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022689-A1 | C4-SPIRO-PYRROLIDINE ANTIVIRALS | ZC3HAV1, HAVCR2, HCCS | MAPT 4728/4885TSHR 3837/4885ALDH1A1 274/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | MAPT 4428/4885TSHR 4355/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.